Von Vascular has announced what it describes as “compelling” new in-vivo data on its Algo smart pump featuring adaptive pulsatile aspiration (APA). These data were presented during a late-breaking session at the Society of Vascular and Interventional Neurology (SVIN) annual meeting (19–22 November 2025, Orlando, USA) by Robert Starke (University of Miami, Miami, USA).
In a presentation titled, ‘Adaptive pulsatile aspiration leads to improved thrombectomy outcomes during in-vivo large vessel occlusion for acute ischaemic stroke’, Starke detailed the results of a preclinical animal study, detailing how usage of the Algo smart pump enhanced clot ingestion and reduced the risk of distal emboli during thrombectomy as compared to static aspiration.
He also highlighted evidence showing that current static aspiration systems ‘cork’ the clot at the catheter tip as much as 80% of the time, potentially increasing the likelihood of clot fragmentation and microvascular occlusions—issues that, according to Von Vascular, may go undetected by angiography and contribute to poor patient outcomes. The company further claims that, by contrast, its Algo smart pump’s APA feature results in higher rates of complete clot ingestion and fewer micro-emboli.
During his presentation, Starke described Algo as a smart pump that “actively listens” to the clot by responding to real-time pressure feedback at the catheter tip to dynamically modulate aspiration. Unlike traditional pumps that apply static suction, Algo uses a computer-guided, adaptive approach that responds to clot behaviour in real time to enhance capture while protecting surrounding vessels.
In the present study, use of the Algo smart pump with APA achieved an 83.3% complete clot ingestion rate compared to 40% with a standard static aspiration system (p=0.014), while the first-pass effect rate was 80% with Algo versus 40% with static aspiration (p=0.041). These findings suggest that Algo’s dynamic aspiration strategy may more meaningfully improve procedural efficiency and early revascularisation, Von Vascular’s release adds.
Starke concluded by underscoring the importance of the first-pass effect in stroke care—and describing Algo as a shift from “bigger is better” to “smarter aspiration”.
Von Vascular notes in its recent release that the Algo smart pump is not commercially available in the USA but is currently progressing through regulatory pathways, with a commercial launch targeted for next year.
